Informatics-Based Digital Application to Promote Safe Exercise in Middle-Aged Adults with Type 1 Diabetes
Project Number5K01DK129441-03
Former Number1K01DK129441-01
Contact PI/Project LeaderASH, GARRETT IGO
Awardee OrganizationYALE UNIVERSITY
Description
Abstract Text
ABSTRACT
Type 1 diabetes (T1D) affects ~1 million American adults and increases the risk of mortality attributable to
cardiovascular disease by 800%. Current evidence-based T1D self-management interventions target glycemic
control but ignore other modifiable health concerns prevalent in T1D such as hypertension and obesity. Exercise
interventions could provide a novel solution if they could innovatively address the diabetes management and
psychosocial challenges around exercise posed by T1D. Continuous glucose monitoring (CGM) allows patients
and providers to comprehensively track the short- and long-term outcomes of exercise. Evidence-based
interventions to translate CGM technology into sustainable adherence to exercise-related behaviors are lacking.
Our human-delivered pilot intervention provided previously sedentary adults with T1D access to exercise videos
and monthly client-centered discussions of their CGM and exercise data with an exercise coach. Participants
said these improved exercise management behavioral skills and motivation, but only transiently. They stated a
need for more frequent and sustained contact, requiring automated mobile tools that this proposal will develop.
These tools include just-in-time adaptive text messages to overcome exercise barriers at times of vulnerability,
weekly personalized reviews of short-term exercise safety hazards with tips to avoid them, and monthly
personalized evaluation of long-term impact of exercise on blood glucose levels via Bayesian modeling. The
program represents stage 1 of the NIH intervention development model: intervention generation, refinement,
modification, adaptation. These steps will be accomplished by a feasibility study evaluating user satisfaction and
mathematical robustness of an alpha version, using these results to modify the alpha version into a beta version,
and then testing the beta version in a nonrandomized crossover clinical trial. Lastly, the databank of
biobehavioral metrics generated by this trial (exercise, CGM, mood and sleep diaries for ~ 7,000 person-days)
will be subjected to dimensionality reduction to identify biobehavioral subtypes of baseline and early intervention
data. We will test whether these subtypes help predict longer-term intervention response and/or flag specific
biobehavioral feature combinations that drive intervention responsiveness. These findings will lay a foundation
for Dr. Ash’s future work developing precision medicine approaches. Alongside this research Dr. Ash will
complete training in the domains of 1) diabetes management and technology; 2) mobile health (mHealth)
intervention development; and 3) dimensionality reduction analytics. The training plan includes a strategic
combination of mentor-led trainings, coursework, grant writing, and attendance at relevant conferences and
workshops. Dr. Ash has assembled a mentoring team in T1D self-management and technology, multiple health
behavior change intervention development, mHealth development, and informatics. FitscriptLLC and PiLR Health
will provide customized intervention tools and data capture software. Dr. Gerstein’s laboratory will support data
storage, processing, and analytics.
Public Health Relevance Statement
PROJECT NARRATIVE
The challenges of living with type 1 diabetes often stand in the way of getting enough exercise. Continuous blood
sugar monitoring has revolutionized type 1 diabetes care but remains underutilized to sustainably support
exercise and related behaviors. This research will develop a mobile application that delivers personalized
encouragement and data-driven health insights based upon patterns in blood sugar, exercise, mood, and sleep,
to assist people with type 1 diabetes in exercising more frequently and confidently.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
043207562
UEI
FL6GV84CKN57
Project Start Date
01-September-2022
Project End Date
31-August-2027
Budget Start Date
01-September-2024
Budget End Date
31-August-2025
Project Funding Information for 2024
Total Funding
$147,741
Direct Costs
$136,797
Indirect Costs
$10,944
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Diabetes and Digestive and Kidney Diseases
$147,741
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5K01DK129441-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K01DK129441-03
Patents
No Patents information available for 5K01DK129441-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K01DK129441-03
Clinical Studies
No Clinical Studies information available for 5K01DK129441-03
News and More
Related News Releases
No news release information available for 5K01DK129441-03
History
No Historical information available for 5K01DK129441-03
Similar Projects
No Similar Projects information available for 5K01DK129441-03